Login to Your Account

Covagen Inks $146M Fynomer Discovery Pact with Mitsubishi

By Cormac Sheridan
Staff Writer

Thursday, October 18, 2012

Covagen AG signed its first drug discovery deal, a pact worth potentially up to €112.25 million (US$146 million) with Mitsubishi Tanabe Pharma Corp. that involves its Fynomer protein scaffold technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription